LOZANOC® / TOLSURA® is an orally administered antifungal agent with the active ingredient itraconazole.

SUBA® technology brings improved bioavailability

LOZANOC® / TOLSURA® have approximately double the bioavailability of the conventional itraconazole formulation. This greater bioavailability compared with conventional formulations is achieved using the SUBA manufacturing process, a proprietary technology developed by Mayne Pharma. SUBA technology utilizes a solid dispersion of drug in a polymer matrix to improve the dissolution of poorly soluble drugs resulting in improved absorption of these drugs in the gastrointestinal tract.

Developed and Manufactured in Australia

LOZANOC® / TOLSURA® are manufactured by Mayne Pharma at our development and manufacturing facility in South Australia. Mayne Pharma is a technology-driven pharmaceutical company with a well-established track record of innovation and success in developing new oral drug delivery systems. In Australia and the US, Mayne Pharma commercially launched this product through its dedicated specialty sales team.

We currently have distribution partners for LOZANOC® in the following countries:  Argentina, Austria,  Chile, Columbia, Germany, Israel, Italy, Mexico, Peru, Portugal, Spain and the Middle-East.

Opportunities remain for licensing.